《艾昆纬：2024患者等待获取创新疗法（W.A.I.T.）指标调查报告：2023年结果（英文版）（61页）.pdf》由会员分享，可在线阅读，更多相关《艾昆纬：2024患者等待获取创新疗法（W.A.I.T.）指标调查报告：2023年结果（英文版）（61页）.pdf（61页珍藏版）》请在三个皮匠报告上搜索。

1、 2024.All rights reserved.IQVIAis a registered trademark of IQVIA Inc.in the United States,the European Union,and various other countries.Published June 2024EFPIA Patients W.A.I.T.Indicator 2023 SurveyMax Newton,Engagement Manager,GS&ARKelsey Stoddart,Consultant,GS&ARMarco Travaglio,Consultant,GS&AR

2、Per Troein,VP,Strategic Partners1Indicators measure availability,limited availability and time to local authorisation datesThis years Patients W.A.I.T.indicator covers 36 countries and includes the full EU27 countriesData not available/included Data availableEuropean countriesyear cohort(19-22)364in

3、novative medicines167Foreword from the IQVIA project team:The Patients W.A.I.T.(Waiting to Access Innovative Therapies)Indicator has been running in evolving formats since 2004,and is the largest European study into innovative medicines availability and the time to patient access.It shows a set of K

4、ey Performance Indicators(KPIs)on the European access environment for innovative medicines across 5 cohorts of medicines(all medicines,oncology,orphan medicines,non-oncology orphan medicines,and combination therapies)to show how different segments of the market are prioritised and how the market acc

5、ess landscape varies.The charts in the following report includes data on 36 countries(27 EU,and 9 non-EU),giving a full European picture of availability.Information on the 167 innovative medicines with central-marketing authorisation between 2019 and 2022 are included,with the study running on a one

6、 year delay to permit countries to include these medicines on their public reimbursement list,meaning that the data on availability is accurate as of January 5th2024.This period is therefore inclusive of the COVID-19 pandemic.Although no significant impact is noted in the indicator,the continued imp